CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,284,548 | +85.5% | 1,589,931 | +12.4% | 3.14% | +106.2% |
| Q2 2023 | $25,495,110 | +12.2% | 1,414,823 | 0.0% | 1.52% | -7.4% |
| Q1 2023 | $22,722,057 | -12.2% | 1,414,823 | 0.0% | 1.64% | +2.2% |
| Q4 2022 | $25,891,261 | -6.8% | 1,414,823 | 0.0% | 1.61% | -24.8% |
| Q3 2022 | $27,787,000 | +5.3% | 1,414,823 | 0.0% | 2.14% | -14.1% |
| Q2 2022 | $26,386,000 | -15.0% | 1,414,823 | 0.0% | 2.49% | -5.9% |
| Q1 2022 | $31,055,000 | – | 1,414,823 | – | 2.65% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |